Arcus Biosciences RCUS Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's deferred revenue?
- Arcus Biosciences (RCUS) reported deferred revenue of $34M in Q1 2026.
- How has Arcus Biosciences's deferred revenue changed year-over-year?
- Arcus Biosciences's deferred revenue decreased by 52.8% year-over-year, from $72M to $34M.
- What is the long-term trend for Arcus Biosciences's deferred revenue?
- Over 5 years (2020 to 2025), Arcus Biosciences's deferred revenue has grown at a -14.0% compound annual growth rate (CAGR), from $74.57M to $35M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.